Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 9/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL741720 | 0.98 | HRH4 (0.57) | HRH4HRH3PTGS1PTGS2RAB9A | |
| SCHEMBL3498537 | 0.87 | EGLN1 (0.67) | HRH4HRH3PTGS1PTGS2RAB9A | |
| SCHEMBL20646875 | 0.84 | HRH4 (0.61) | HRH4HRH3RAB9AKDM4EALDH1A1 | |
| SCHEMBL3764713 | 0.84 | HRH4 (0.57) | HRH4HRH3RAB9AKDM4EALDH1A1 | |
| SCHEMBL19017784 | 0.83 | HRH4 (0.57) | HRH4HRH3RAB9AKDM4EALDH1A1 | |
| Lithium Ion SCHEMBL741719 | 0.83 | HRH4 (0.56) | HRH4HRH3RAB9AKDM4EALDH1A1 | |
| SCHEMBL4211423 | 0.82 | RAB9A (0.53) | HRH4HRH3PTGS1PTGS2RAB9A | |
| SCHEMBL4213158 | 0.81 | HRH4 (0.55) | HRH4HRH3RAB9AKDM4EALDH1A1 | |
| SCHEMBL20646876 | 0.80 | HRH4 (0.57) | HRH4HRH3RAB9AKDM4EALDH1A1 | |
| SCHEMBL2638074 | 0.80 | PTGS1 (0.59) | HRH4HRH3PTGS1PTGS2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310356-B1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2013-08-14 | — | — | EP | claimed |
| JP-2011529057-A | — | — | 2011-12-01 | — | — | JP | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| WO-2010011570-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | WO | claimed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | claimed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| CN-120058672-A | Halogenated pyridylcarboxylic acid ester derivative and application thereof | 贵州医科大学 | 2025-05-30 | — | — | CN | disclosed |
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| EP-1778685-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2007-05-02 | — | — | EP | disclosed |
| US-20060211747-A1 | Methods of screening for compounds which inhibit the activity of Cdc34 in a zinc-mediated manner and compounds obtained by this method | FURET PASCAL | 2006-09-21 | — | — | US | disclosed |
| WO-2006015737-A1 | INDOLIZINE CARBOXAMIDES AND THE AZA AND DIAZA DERIVATIVES THEREOF | SCHWARZ PHARMA AG (DE) | 2006-02-16 | — | — | WO | disclosed |
| US-6013654-A | Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases | PHARMACIA & UPJOHN COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-5912246-A | Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0809642-A1 | IMIDAZO 1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025414-A1 | IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | HRH4 427/4885HRH3 355/4885PTGS1 3174/4885 |
| US-20060211747-A1 | Methods of screening for compounds which inhibit the activity of Cdc34 in a zinc-mediated manner and compounds obtained by this method | CDC45, CDC37, CDC5L | HRH4 3594/4885HRH3 3140/4885PTGS1 3930/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | HRH4 1562/4885HRH3 1776/4885PTGS1 3990/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | HRH4 267/4885HRH3 857/4885PTGS1 542/4885 |
| US-20250388595-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS | EIF2B1, EIF4EBP1, EIF2B3 | HRH4 3252/4885HRH3 3684/4885PTGS1 2008/4885 |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | HRH4 1224/4885HRH3 866/4885PTGS1 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.